Methyl 4-Bromo-2-cyanobenzoate - CAS 1223434-15-8
Catalog: |
BB059907 |
Product Name: |
Methyl 4-Bromo-2-cyanobenzoate |
CAS: |
1223434-15-8 |
Synonyms: |
METHYL 4-BROMO-2-CYANOBENZOATE; Benzoic acid, 4-bromo-2-cyano-, methyl ester; METHYL4-BROMO-2-CYANOBENZOATE |
IUPAC Name: | methyl 4-bromo-2-cyanobenzoate |
Description: | methyl 4-bromo-2-cyanobenzoate (cas# 1223434-15-8) is a useful research chemical. |
Molecular Weight: | 240.05 |
Molecular Formula: | C9H6NO2Br |
Canonical SMILES: | COC(=O)C1=C(C=C(C=C1)Br)C#N |
InChI: | InChI=1S/C9H6BrNO2/c1-13-9(12)8-3-2-7(10)4-6(8)5-11/h2-4H,1H3 |
InChI Key: | APAVVMSHHACFQV-UHFFFAOYSA-N |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
WO-2022047145-A1 | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use | 20200828 |
TW-202045491-A | Azole derivatives | 20190220 |
WO-2020171146-A1 | Azole derivative | 20190220 |
AU-2018249675-A1 | New compounds inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma. | 20170406 |
CN-110709396-A | Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma | 20170406 |
EP-3606921-A1 | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma. | 20170406 |
KR-20190137803-A | Novel compounds that are inhibitors of BPA / TAA-TEAD interactions and their use in the treatment of malignant mesothelioma | 20170406 |
US-2020115353-A1 | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma | 20170406 |
WO-2018185266-A1 | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma. | 20170406 |
AU-2018215212-A1 | Cereblon ligands and bifunctional compounds comprising the same | 20170131 |
Complexity: | 245 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 238.95819 |
Formal Charge: | 0 |
Heavy Atom Count: | 13 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 0 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 238.95819 |
Rotatable Bond Count: | 2 |
Topological Polar Surface Area: | 50.1Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 2.2 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
-
[79407-66-2]
3-(2,4-Dihydroxyphenyl)-2-propenal
-
[868161-59-5]
(E,E)-5-[4-(Diethylamino)phenyl]penta-2,4-dienal
-
[1212679-29-2]
(3R,4R)-N-(3-Cyanophenyl)-3-[[4-[(4-fluorophenyl)methoxy]benzoyl]amino]hexahydro-4-hydroxy-1H-azepine-1-carboxamide
-
[1354469-76-3]
(3R,4R)-N,4-Dimethyl-piperidin-3-amine
-
[24177-07-9]
(2R,5S,10aS,10bS)-Octahydro-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxo-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazine-2-carboxylic Acid
-
[1456707-58-6]
(2R,6S)-2,6-Dimethyl-4-((R)-2-methyl-3-(4-(tert-pentyl)phenyl)propyl)morpholine-hydrochloride
Customers Also Viewed
-
[94086-78-9]
Isopropyl 4-[4-[N,N-bis(2-hydroxyethyl)amino]phenyl]butyrate
-
[1866059-82-6]
1,1,2,2-Tetrafluoro-3-methylsulfonylpropane
-
[172531-37-2]
Azido-PEG3-acetic acid
-
[14245-62-6]
Isopropyl ethanesulfonate
-
[1427004-19-0]
DBCO-PEG4-NHS ester
-
[132182-92-4]
Pentane, 1,1,1,2,2,3,4,5,5,5-decafluoro-3-methoxy-4-(trifluoromethyl)-
INDUSTRY LEADERS TRUST OUR PRODUCTS